Wenjing Li

Wenjing Li is a seasoned scientist with extensive expertise in immunology and cell therapy. Currently serving as a Senior Principal Scientist at Genentech since 2024, prior roles include Senior Principal Scientist at Allogene Therapeutics, where leadership was provided for blood and solid tumor Allogeneic CART programs, and significant advancements were made in latent virus control strategies. Wenjing also held positions as Principal Scientist at AbbVie, leading a switchable CART therapy program, and as Senior Scientist II at Sidra Medical and Research Center, focusing on novel immunotherapies. Earlier research included roles at the Icahn School of Medicine at Mount Sinai, where work centered on host anti-viral immunity and vaccine development. Wenjing Li holds a PhD in Immunology from Peking Union Medical College and a BS in Biochemistry from Wuhan University.